Larimar Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2026 Annual Meeting of Stockholders held virtually on May 19, 2026. As of the record date of March 25, 2026, there were 103,882,937 outstanding shares of common stock entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Stockholders approved all six proposals submitted at the Annual Meeting:
- Proposal 1 (Election of Directors): Frank Thomas, Carole S. Ben-Maimon, M.D., and Joseph Truitt were elected as Class III directors to serve until the 2029 Annual Meeting.
- Proposal 2 (Say-on-Pay): Stockholders approved the 2025 compensation of named executive officers on an advisory basis.
- Proposal 3 (Say-on-Pay Frequency): Stockholders indicated a preference for annual advisory votes on executive compensation. The Board will hold such votes every year until the next required frequency vote.
- Proposal 4 (Auditor Ratification): The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the 2026 fiscal year was ratified.
- Proposal 5 (Charter Amendment): Stockholders approved an amendment to increase the number of authorized shares of Common Stock from 115,000,000 to 215,000,000.
- Proposal 6 (Adjournment): Stockholders approved a conditional adjournment proposal, which was not necessary as Proposal 5 was approved.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items beyond the voting results.
Investor Verification Checklist
- Verify the effective date of the charter amendment increasing authorized shares to 215,000,000.
- Review the definitive proxy statement filed on April 20, 2026, for detailed biographies of the newly elected directors.
- Confirm the specific terms of the 2025 executive compensation package approved in Proposal 2.
- Monitor future filings for the implementation of the annual say-on-pay frequency decision.